Growing Public Awareness of Autoimmune Disease
The rising awareness about autoimmune diseases through programs of research, education, support, and advocacy is a key factor boosting the usage rates. It is imperative that the public is more aware of their own risk factors for developing auto-immune diseases so that, as symptoms occur, they can seek diagnosis, and begin a treatment regimen. The United States has the highest incidence of autoimmune diseases where, about 50 million patients suffer from autoimmune diseases. The American Autoimmune Related Diseases Association (AARDA) aims to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. Similarly, there are other organizations who are striving to improve the R&D funding, patient awareness, and provide other socio-economic benefits to the patients. Moreover, the increase in awareness levels coupled with improving healthcare infrastructure and reimbursement coverage is expected to drive the market over the forecast period. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, technological advancements and expansion in coverage allowed by the Patient Protection and Affordable Care Act are driving the North American autoimmune disease diagnostics market.
Slow Turnaround Time for Diagnostic Test Results
Diagnosis of auto-immune diseases is a time-consuming process. It involves procedures such as serum testing for diseases like rheumatoid arthritis, Addison’s disease, Hashimoto’s disease, and others. Testing protocols allow autoimmune disorders to be diagnosed in a highly efficient, cost-effective manner. However, the turnaround time for the test results is slow, owing to lesser automation techniques. It takes days to deliver all test results to the patients with proper explanation of false positive results. For example autoimmune lymph proliferative syndrome is an autoimmune disease with a turnaround time of up to 12 weeks. A single gene sequencing takes four weeks.Therefore, this slow turnaround time is hindering the North American autoimmune disease diagnostics market. The other factor such as the high frequency of false positive result is also hindering the growth of the market.
United States Leads the Market in North America
The United States autoimmune disease diagnostics market held the largest market share, in 2017, in North America due to the increasing healthcare expenditure and increasing prevalence of autoimmune diseases in this region. In the United States, 16% of the population suffers from autoimmune diseases, 78% of whom are women.
Key Developments in the Market
- October 2017: The US Food and Drug Administration cleared Roche's CobasCdiff Nucleic acid test.
- August 2017: BioMerieux, received SERVICE 800 award in an annual conference held in Minneapolis.
- August 2017: Thermo Fisher Scientific acquired the Patheon.
Reasons to Purchase the Report
- Follow the current and future North American autoimmune disease diagnostics market in the developed and emerging markets.
- Examining the various perspectives of the market with the help of Porter’s Five Forces Analysis
- Identify the segment that is expected to dominate the market.
- Identify the regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1.1 Growing Public Awareness of Autoimmune Disease
6.1.2 Improved Laboratory Automation
6.1.3 Partnerships with Physicians and Clinical Laboratories
6.1.4 Technological Advancements
6.1.5 Expansion in Coverage Allowed by Patient Protection and Affordable Care Act
6.2.1 Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results
6.2.2 High Frequency of False Positive Result
6.4 Key Challenges
7. Market Segmentation
7.1 By Disease Type
7.1.1 Systemic Autoimmune Disease
220.127.116.11 Rheumatoid Arthritis
18.104.22.168 Systemic Lupus Erythematosus (SLE)
22.214.171.124 Multiple Sclerosis
7.1.2 Localized Autoimmune Disease
126.96.36.199 Inflammatory Bowel disease
188.8.131.52 Type 1 Diabetes
7.2 By Diagnosis
7.2.1 Immunofluorescence Assays (IFA)
7.2.2 Enzyme-linked Immunosorbent Assay (ELISA)
7.2.3 Western Blotting
7.2.4 Dot blot
7.2.5 Line blot
7.2.6 Multiplex Immunoassay
7.2.8 Double Immune Diffusion
7.2.9 Counter Immune-electrophoresis
7.3 By Geography
7.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 Australia & New Zealand
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.3.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of the Middle East & Africa
7.3.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott Laboratories
9.3 Bio-rad Laboratories
9.4 Euroimmun AG
9.5 F. Hoffmann-la Roche
9.6 Inova Diagnostics, Inc.
9.7 Myriad Genetics
9.8 Siemens Healthineers, Inc.
9.9 Thermo Fisher Scientific
9.10 Trinity Biotech
*List not Exhaustive
10. Future of the Market